恶性黑素瘤的免疫治疗进展  

Immunotherapy for malignant melanoma

作　　者：侯晓阳[1] 杨春生[1] 孙超[1] 刘彦群[1] 魏志平[1] 蒋冠[1] 

机构地区：[1]徐州医学院附属医院皮肤科,江苏221002

出　　处：《国际皮肤性病学杂志》2016年第5期397-400,共4页International Journal of Dermatology and Venereology

基　　金：国家自然科学基金（81372916、81572976）;江苏省自然科学基金（BK20141142）

摘　　要：恶性黑素瘤是一种恶性度高、侵袭性强的难治性皮肤肿瘤，对传统治疗方法如放疗和化疗不敏感，疗效不令人满意。免疫学方法治疗恶性黑素瘤已成为研究热点。免疫学方法是一种用免疫细胞或免疫制剂来调节机体的免疫状态，从而治疗疾病的方法，具有特异性强、不良反应小等优点。可以通过多种治疗方式如细胞因子治疗、过继细胞治疗和特异性免疫治疗等单独或联合应用于恶性黑素瘤的治疗，具有较高的有效率并延长了患者的生存期，为治疗恶性黑素瘤带来了希望。Malignant melanoma （MM） is a kind of highly malignant and strongly invasive refractory skin neoplasm, and poorly responds to traditional therapies such as radiotherapy and chemotherapy. Immunotherapy for MM has become a research hotspot. Immunotherapy is a treatment approach that can regulate the immune system through immune cells or immunoagents, and has the advantages of strong specificity and less adverse effects. A variety of immunotherapies, such as cytokine therapy, adoptive cellular therapy and specific immunotherapy, have been applied alone or in combination in MM. These immunotherapies have shown high efficacy, lengthened survival time of patients, and brought hopes for the treatment of MM.

关 键 词：黑色素瘤 免疫 细胞因子类 杀伤细胞 淋巴因子激活 抗体 单克隆 癌症疫苗 

分 类 号：R739.5[医药卫生—肿瘤]